Cargando…

Thirteen‐year trends in risk scores predictive values for subsequent stroke in patients with acute ischemic event

INTRODUCTION: A high residual risk of subsequent stroke suggested that the predictive ability of Stroke Prognosis Instrument‐II (SPI‐II) and Essen Stroke Risk Score (ESRS) may have changed over the years. AIM: To explore the predictive values of the SPI‐II and ESRS for 1‐year subsequent stroke risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Yunyun, Wang, Shang, Li, Zixiao, Fisher, Marc, Wang, Liyuan, Jiang, Yong, Huang, Xinying, Zhao, Xing‐Quan, Meng, Xia, Wang, Yongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176011/
https://www.ncbi.nlm.nih.gov/pubmed/36978218
http://dx.doi.org/10.1002/brb3.2962
Descripción
Sumario:INTRODUCTION: A high residual risk of subsequent stroke suggested that the predictive ability of Stroke Prognosis Instrument‐II (SPI‐II) and Essen Stroke Risk Score (ESRS) may have changed over the years. AIM: To explore the predictive values of the SPI‐II and ESRS for 1‐year subsequent stroke risk in a pooled analysis of three consecutive national cohorts in China over 13 years. RESULTS: In the China National Stroke Registries (CNSRs), 10.7% (5297/50,374) of the patients had a subsequent stroke within 1 year; area under the curve (AUC) of SPI‐II and ESRS was .60 (95% confidence interval [CI]: .59–.61) and .58 (95% CI: .57–.59), respectively. For SPI‐II, the AUC was .60 (95% CI: .59–.62) in CNSR‐I, .60 (95% CI: .59–.62) in CNSR‐II, and .58 (95% CI: .56–.59) in CNSR‐III over the past 13 years. The declining trend was also found in ESRS scale (CNSR‐I: .60 [95% CI: .59–.61]; CNSR‐II: .60 [95% CI: .59–.62]; and CNSR‐III: .56 [95% CI: .55–.58]). CONCLUSIONS: The predictive power of the traditional risk scores SPI‐II and ESRS was limited and gradually decreased over the past 13 years, thus the scales may not be useful for current clinical practice. Further derivation of risk scales with additional imaging features and biomarkers may be warranted.